Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab 1000 vs Prolia in postmenopausal osteoporosis
2021-006545-36Phase 3Completed
- Sponsor
- Mylan
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DenOsteoRel in osteoporosis (2 arms), sponsored by Mylan. Primary endpoint: Co-primary endpoint: Lumbar spine BMD percentage change at Week 52. Started Feb 2022; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2021-006545-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006545-36.